

**Date: 29<sup>th</sup> August, 2024**

**To,  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai- 400051  
NSE Symbol: VAISHALI**

**Subject: Press Release: Vaishali Pharma Ltd recommends 1:1 Bonus Issue and 1:5 Stock Split; Expects to continue it's Strong Growth Momentum with Innovation**

Dear Sir,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on the captioned subject being issued today.

Kindly take the above information on your records.

Thanking You,

Yours Faithfully,

**For Vaishali Pharma Limited**

**Atul Arvind Vasani  
Managing Director**

ENCL: As above

**Media Release**

**Vaishali Pharma Ltd recommends 1:1 Bonus Issue and 1:5 Stock Split; Expects to continue it's Strong Growth Momentum with Innovation**

Company's Board recently approved stock split of 1 Equity share of Rs. 10 face value in to five equity shares of Rs. 2 each

**Highlights**

- *Bonus issue is aimed at to reward existing shareholders, enhance liquidity, and expand the shareholder base.*
- *Consideration of stock split and bonus shares are in line with the company's vision to reward the shareholders and earn their long-lasting trust and confidence*
- *Company had recently obtained 19 registrations across Southern Africa, West Africa, the Gulf region, Latin America etc, expected to contribute around Rs. 100 million to the company's annual revenue.*
- *Mumbai-based pharma company has over 250 + formulation brands marketed in multiple countries and a robust pipeline of around 250 Dossiers*

**Mumbai, 28 August, 2024** - Board of directors of Mumbai based [Vaishali Pharma Ltd](#) (NSE – VAISHALI) has recommended issue of bonus equity shares in the ratio of 1:1 (1 Bonus share equity for every 1 equity share held in the company as on the record date) in the meeting held on August 28, 2024 along with stock split, subject to necessary regulatory and shareholders' approvals. Company approved sub-division of 1 equity share of Rs. 10 face value into five equity shares of Rs. 2 face value each. The bonus issue is aimed at reward existing shareholders, enhance liquidity, and expand the shareholder base.

The board also considered proposal for raising of fund by way of equity shares, debentures or other securities through rights issue, private placement, qualified institutions placement (QIP), preferential issue or any other method.

Catering to semi-regulated and non-regulated markets across the world, the company had recently obtained 19 registrations across Southern Africa, West Africa, the Gulf region, Latin America and ASEAN region. These registrations are poised to contribute around Rs. 100 million to the company's annual revenue.

Backed by strong product portfolio and distribution network, the Company had reported robust financial performance for Q1FY25. For the quarter ended on June 30, 2024, the Company's sales increased by 34.70% to Rs 18.08 crore in Q1FY25 compared to Rs 13.42 crore during Q1FY24. Net Profit of the company rose 7.13% to Rs 1.70 crore as against Rs 1.59 crore during the previous quarter ended June 2023.

Commenting on the development, **Mr. Atul Vasani, Chairman and Managing Director, Vaishali Pharma Ltd** said, "We are proud to inform our stakeholders that the company is making significant strides in its long-term growth strategy, delivering excellent operational and financial results. Consideration of stock split and bonus shares are in line with the company's vision to reward the shareholders and earn their long-lasting trust and confidence. This move will not only reward our existing shareholders for their continued support but also increase the company's equity base, thereby enhancing liquidity. With a focus on growth and innovation, the company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector."

Established in 1989, Vaishali Pharma Limited specializes in the production and marketing of a diverse range of pharmaceutical products, including APIs, formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products. Their portfolio serves both human and animal healthcare needs. The company has over 250 + formulation brands marketed in multiple countries and a robust pipeline of around 250 Dossiers. The company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients. Company is one of the fastest-growing and most versatile company in the pharmaceutical industry. It has a strong presence in both the domestic and export markets and is currently supplying to all leading Indian and international companies.



As an emerging force, Vaishali Pharma is poised to contribute substantially to the pharmaceutical landscape in India. The company had recently announced the launch of its new brand “HealthE” for local online market. The first product in this lineup is HealthE Biotin and Multivitamin Gummies is a revolutionary product designed to enhance hair, skin, and overall health. These delectable gummies combine the power of biotin, essential vitamins, and natural extracts to support hair growth, promote radiant skin, and boost overall vitality. All the products launched are backed by food scientist. This exciting development is a testament to the company's ongoing commitment to delivering health and wellness solutions that improve lives and promote lasting well-being. The company plans to add many more products in near future.

"Our venture into the Nutraceutical Products segment, in addition to our ongoing collaborations and alliances, is poised to serve as pivotal growth catalysts in the future. We eagerly anticipate the continuation of our journey towards excellence, with the utmost focus on delivering value to our stakeholders and making significant contributions to the enhancement of healthcare worldwide. Our unwavering dedication to innovation, commitment to maintaining high-quality standards, and the strategic expansion of our global footprint through valuable partnerships have been instrumental in driving our success", added **Mr. Vasani**.

With a vision “To be a well-recognised Indian MNC in the pharmaceuticals and healthcare industry”, the company continue to work on its mission to contribute substantially towards well-being and health of the society by providing high quality products and service.

**For more details please visit:** [www.vaishalipharma.com](http://www.vaishalipharma.com)

**For any Investor Relations query, please contact:**

**Mr. Ratnesh Singh**  
**Chief Financial Officer**  
Email: [investor@vaishalipharma.com](mailto:investor@vaishalipharma.com) , [cs@vaishalipharma.com](mailto:cs@vaishalipharma.com)

**Note:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.